Ezgi Antmen

The paper introduces a microfluidic T-Chip for one-step clinical-scale T-cell purification from blood products, achieving high purity, viability, and recovery of CD3+ T cells for CAR T-cell manufacturing.

The paper identifies HECTD4 as a tumor and metastasis suppressor that targets COX-2 for degradation, with COX-2 stabilization driving pro-tumorigenic effects in breast cancer.

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.